In vitro comparative activity of meropenem with 15 other antimicrobial agents against 1798 Pseudomonas aeruginosa isolates in a French multicenter study  by Husson, M.O. et al.
Concise  C o m m u n i c a t i o n s  499  
In vitro comparative activity of meropenem with 15 other antimicrobial 
agents against 1798 Pseudomoms aemginosa isolates in a French multicenter 
study 
Clin Micvobiol Infect 1999; 5: 499-503 
M. 0. Hiissoti I * ,  H.  Richet", A. Aidbertj,  C .  Cat toen4,  A .  Chardon5,  VJarl ier6,  D. Izard ', 
E. Lecailloii7, M.  Melot la ,  A .  Morel' a d  M.  H. Nicolas" 
Laboratoire de BactPriologie-HygiPne, FacultP de Mkdecine H. Warembourg, 1 place de Verdun, 
59045 Lille cedex, France; Laboratoires de BactPriologie, 'CHU Nantes, 3CHG Saint Etienne, 
'CHG Valenciennes, 'CHG Aix en Provence, %HU PitiP-SalpPtriire, Paris, 'CHG Perpignan, 
'CHG Pau, 9CHG Le Havre, '"CHU Ambroise Par6 Paris, France 
*Tel: 03 20 44 55 73 Fax: 03 20 52 93 61 
Accepted 27 November 1998 
INTRODUCTION 
Pseirdornorzas aen4ginosa is one of the most common 
pathogens involved in hospital-acquired infections. 
In recent years, a number of studies have reported an 
increased incidence of multiresistant strains [l-31 
through the acquisition of plasmid-encoded p-lacta- 
niases [4], or aminoglycoside-modifying enzymes [5] 
and mutations. Mutational events are involved in the 
hyperproduction of the AmpC (class I) chromosomal 
p-lactamase that confers resistance to antipseudomonal 
penicillins and cephalosporins [6], the alteration of 
DNA gyrase that results in resistance to quinolones [7], 
the loss of the OprD2 porin in relation to imipenem 
resistance [8,9], and the changes in the structure and 
energetics of the membrane that reduce drug accumu- 
lation by accelerating niultidrug efflux [lo]. Because of 
this variety of resistance mechanisms, treatment of 
pseudomonal infections is difficult, and high morbimty 
and mortality among patients compromised by surgical 
wounds, burns, trauma and cancer are now observed 
Meropenem is a new carbapenem antibiotic that is 
more stable than imipenem to human renal dehydro- 
peptidase [13] and is more potent against many species, 
including P aevi4ginosa [13]. We studied the activity 
of meropenem, in comparison with 15 other anti- 
microbial agents, against 1798 clinical isolates of P 
aeniginosa collected from 10 French hospitals. The 
distribution of antimicrobial resistance and 0 serotypes 
was also examined according to hospital. 
One thousand seven hundred and ninety-eight 
consecutive single clinical isolates of I? aevuginosa were 
collected over a period of 6 months (March to 
September 1996) from 10 hospital laboratories 
[111. 
throughout France. Multiple isolates from the same 
patient were excluded if they belonged to the same 
serotype and had the same resistance pattern. Deter- 
mination of the 0 serotype was made by slide 
agglutination with a set of four pools (OMA, OMC, 
OME, OMF) and 16 monovalent antisera numbered 
0 1  to 016  (Sanofi Diagnostics Pasteur, Paris, France). 
The susceptibility to antibiotics was determined by 
the disk diffusion method using the same lot of 
Mueller-Hinton agar and the following disks provided 
by Sanofi Diagnostics Pasteur: ticarcillin (75 mg), 
ticarcillinSc1avulanate (75/10 mg), piperacillin (75 mg). 
piperacillin+tazobactam (75/10 mg), aztreonam 
(30 mg), ceftazidime (30 mg), cefepiine (30 nig), 
cefsulodine (30 mg), imipenem (10 mg), meropenem 
(10 mg), gentamicin (15 mg). tobramycin (10 mg), 
netilmycin (30 mg), amikacin (30 mg), ciprofloxacin 
(5 mg), fosfomycin glucose 6-phosphate (50 mg). The 
zone sizes used to classify the strains as susceptible or 
resistant were defined by the CA of SFM [14]. 
When the isolate was resistant to ticarcillin, mini- 
mum inhibitory concentrations (MICs) of antibiotics 
were determined by an agar dilution method with 
Mueller-Hinton agar. Aliquots of 5 X lo4 CFU per spot 
were inoculated on agar plates that contained two-fold 
serial dilutions of antibiotics. The MIC was the lowest 
concentration of antibiotic that completely inhibited 
visible growth after incubation for 18 h at 37OC. 
The susceptibilities determined by the disk dihsion 
test for the 1798 strains of I? aenrginosa are reported in 
Table 1. Meropenem was the most potent agent, with 
a rate of susceptible isolates of 89.2%. For the other p- 
lactams, the rates of susceptible strains were as follows: 
ceftazidime 87.2%, imipenem 84.9%, piperacillin+ 
tazobactam 84.7%, piperacillin 81.7%, aztreonam 
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Table 1 Antibiotic susceptibility (disk dffusion test) of 1798 F! aeruginosa clinical isolates according to centers (1-10) 
~ ~ _____ _ _ _ _ _ ~  
% of susceptible isolates for center 
1 2 3 4 5 6 7 8 9 10 All centers 
Anhbiotics (n=196) (n=186) (n=121) (n=192) (n=206) (n=180) (n=188) (n=157) (n=190) (n=182) (n=1798) 
Meropenem 90 91 98 84 78 96 92 85 94 90 89.2 
Ticarcdin 69 64 83 67 71 72 70 68 60 40 65.8 
Ticarcih+ clavulanate 70 67 84 64 49 76 68 62 65 40 63.6 
Piperacillin 87 83 94 75 75 85 85 72 83 82 81.7 
Piperacillin+ tazobactam 88 87 96 77 76 91 88 78 84 86 84.7 
Ceftazidime 87 84 95 78 85 90 94 87 93 84 87.2 
Cefepime 83 76 98 67 70 79 89 ND 75 63 77.0 
Cefiulodine 84 68 93 71 64 86 85 54 80 78 75.9 
Aztreonam 85 87 95 73 80 84 86 79 77 65 80.6 
Gentamkin 57 51 72 45 ND 45 54 52 72 41 53.9 
Tobramycin 81 81 75 58 71 84 71 62 83 54 72.3 
Netilmicin 67 59 91 29 63 63 59 60 71 32 58.4 
Amikacin 86 87 98 67 85 87 81 79 88 67 82.0 
Ciprofloxacin 71 73 69 64 64 72 69 62 72 61 67.6 
Fosfomycin 44 45 88 28 39 31 39 54 57 22 43.0 
Imipenem 87 88 95 79 84 83 86 76 85 91 84.9 
ND, not defined. 
80.6%, cefepime 77%, cefsulodin 75.9%, ticarcihn 
65.8%, and ticarcilhn+clavulanate 63.6%. There were 
also some differences in activity among the other anti- 
biotics tested thus, amikacin, tobramycin and cipro- 
floxacin displayed antibacterial activity by being active 
against 82%, 72.3% and 67.6% of isolates respectively, 
whde gentamicin and fosfomycin were active against 
only 53.9% and 43% respectively. 
The frequency of susceptible isolates varied accord- 
ing to the center. Isolates from center 10, 9, 4 and 2 
were less susceptible to ticarcillin (40-47%), and those 
from centers 2, 4, 5, 8 and 10 less susceptible to 
cefsulodin (6448%) or to cefepime (63-76%), than in 
other centers. Meropenem was the most effective agent 
against all isolates of l? aemginosa collected in each 
center except for centers 5 and 10, in which the rate 
of isolates susceptible to meropenem was similar or 
slightly lower than that of imipenem. 
The most common serotypes were 0 6  (16.9%), 
0 1 1  (11.8%), 0 1  (10.7%), 012  (8.5%), 0 4  (6.6%) 
and 0 3  (6.3%), and 15% of isolates were non-typable. 
However, we noted that the range of serotype fre- 
quencies was particularly wide for serotypes 0 4  
(0-23.1%), 0 1 1  (6.9-23.3%), and 0 1 2  (0.8-18.8%), as 
well as non-typable isolates (1.7-40.4%). Of the 0 1 2  
strains, 39.4% were isolated from patients in intensive 
care units (data not shown) 
The antibiotic susceptibilities of isolates according 
to serotypes are summarized in Table 2. The lowest 
susceptibility to all antibiotics except meropenem, 
ceftazidime and fosfomycin was found in the isolates 
belonging to serotype 012. By comparing the remain- 
ing serotypes and non-typable isolates, we found that 
the isolates belonging to serotype 0 4  were markedly 
less susceptible to ticarcillin alone or associated with 
clavulanate, tobramycin, netilmicin, ciprofloxacin and 
gentamicin, and that the isolates belonging to serotype 
0 1  1 were frequently less susceptible to cephalosporins, 
imipenem and meropenem. 
The MICs obtained for isolates of P aertrginosa that 
were either resistant to ticarcillin and susceptible to 
ceftazidime (group 1: 148 strains) or resistant to ticarcillin 
and ceftazidime (group 2: 156 strains) are summarized 
in Table 3. Most of the strains of group 1 were resistant 
to cefepime, piperacillin, ciprofloxacin and amikacin, 
with rates of susceptible strains of 11.5%, 15.5%, 23% 
and 34.5% respectively. Meropenem and imipenem 
were the most active antibiotics; nevertheless, the MICso 
of meropenem was lower than that of imipenem. In 
group 3, no strain was susceptible to cefepime, and few 
remained susceptible to amikacin and ciprofloxacin 
(26.9% and 17.3% respectively). According to MICs 
obtained for these resistant strains, about 60% of strains 
were susceptible to imipenem or meropenem. Finally, 
meropenem was active against 28.3% of imipenem- 
resistant strains. 
The high incidence of multiresistant P aeruginosa 
isolates in hospital patients demands the development 
of new antibiotics. Most of the resistant strains were 
isolated from intensive care unit patients, where these 
antibiotics are widely used. Alternative drugs will soon 
be needed. The present study compared the in vitro 
activity of meropenem with that of 15 other antibiotics 
against 1798 P aeruginosa strains collected from 10 
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Table 2 I? aenrginora susceptibility (disk di6sion test) accordmg to the most common serotype 
% of susceptible isolates for serotype 
0 1  0 3  0 4  0 6  01  1 0 1 2  NT 
Antibiotics (n=193) (n=113) (n=119) (n=304) (n=212) (n=153) (n=270) 
Meropenem 
Imipeneni 
Ticarcillin 
Ticarcillin + clavulanate 
Piperacillin 
Piperacillin+ tazobactam 
Ceftazidime 
Cefepime 
Cefsulodine 
Aztreonam 
Gentamicin 
Tobramycin 
Netilmicin 
Amikacin 
Ciprofloxacin 
Fosfomycin 
96 
94 
79 
74 
95 
95 
94 
90 
91 
87 
66 
90 
72 
88 
87 
44 
95 
94 
80 
78 
96 
97 
95 
89 
88 
92 
63 
87 
71 
90 
82 
36 
94 
92 
51 
52 
90 
92 
86 
60 
84 
72 
24 
33 
33 
77 
33 
45 
94 
91 
75 
70 
94 
96 
93 
87 
88 
88 
69 
87 
72 
96 
86 
54 
86 
86 
63 
59 
71 
80 
78 
68 
71 
79 
37 
63 
45 
79 
60 
30 
70 
41 
14 
14 
25 
29 
72 
32 
25 
49 
21 
22 
18 
37 
13 
65 
89 
84 
65 
66 
83 
85 
84 
74 
74 
79 
53 
76 
58 
81 
70 
40 
NT, non-typable strains. 
Table 3 MICs (mg/L) of meropenem and other antimicrobial agents against 148 ticarcillin-resistant and cefiazidime-sensitive 
isolates (group l), against 156 ticarcillin- and ceftazidime-resistant isolates (group 2) 
Group 1 n=148 Group 2 n=156 
MIC5o MICqo MIC range % of susceptible MICso hfIC90 MIC range D/o of isolates Antibiotics 
isolates susceptible 
Meropenem 
Imipenem 
Ticarcillin 
Piperacillin 
Cefepime 
Ceftazidime 
Amkacin 
Ciprofloxacin 
Fosfomycin 
1 8 
4 16 
256 1024 
16 32 
2 4 
16 64 
32 64 
32 256 
1024 4096 1 
0.128-32 83.1 
0.25-64 79.7 
1 to >lo24 15.5 
1-64 11.5 
0.5-4 100 
0.128-256 34.5 
0.032 to 1 6 4  23 
1-512 52 
128 to 14096 0 
7 
4 
512 
256 
16 
16 
16 
32 
64 
32 
32 
2048 
1024 
64 
64 
256 
64 
512 
0.128-64 60.3 
0.5-128 62.8 
128 to >4096 0 
16 to >lo24 4.5 
8-256 0 
8-512 it 
1-512 26.9 
0.064 to >64 17.3 
1 to >512 41 
different French centers. The results of this study 
showed that meropenem had the best activity, with a 
rate of susceptible strains of 89.2%. A similar finding 
was noted in other epidemiologic studies, with rates of 
susceptible strains of  90-95.8% [15,16]. 
Susceptibility differences were noted among the 
10 centers participating in the present collaborative 
study. Local variations of antibiotic pressure, but also 
variations in the incidence of some serotype 0 strains, 
might be responsible. Thus, most resistant strains 
belonged to serotype 0 1 2 ,  and the centers with the 
highest rates of resistant strains were correlated with a 
high incidence of serotype 012 .  Thus, most strains of 
serotype 0 12 were resistant to aminoglycosides and 
p-lactam antibiotics as described in other countries 
[17]. Most 0 1 2  isolates displayed a particular profile 
consistent with the hypothesis of only some multi- 
resistant strains spreading through Europe [17,18]. The 
greatest frequency of this serotype in intensive care 
units might explain its selection by drug pressure. 
Meropenem, ceftazidime and fosfomycin were the best 
agents against strains of this serotype. The distribution 
of serotypes 01, 0 3  and 0 6  which included the most 
susceptible strains also varied according to center: they 
were more frequent in centers with low prevalences of 
serotype 0 1 2  than in the others. Their susceptibilities 
to antibiotics were similar to those described in other 
European epidemiologic studies [19,20]. 
Meropenem appeared to be active in vitro against 
many clinical isolates of I? aevtiginosa that are resistant to 
ticarcillin and/or to ceftazidime. This observation is in 
agreement with the findings of other studies that 
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reported meropenem susceptibility in multiresistant 
isolates from patients [21], and with the greater stability 
of meropenem against &eudomonus p-lactamases [3 ,5] .  
Of the two carbapenems, meropenem showed the best 
intrinsic activity, with lower MICSOS against these two 
populations of resistant strains. Furthermore, it was 
effective against 28.3% of imipenem-resistant isolates. 
Simdar meropenem activity against imipenem-resistant 
strains was described by Garcia-Rodriguez et a1 
[15], with 17% of imipenem-resistant strains being 
susceptible to meropenem. As described by Edwards et 
a1 [12], our strains, which remained susceptible to 
rneropenem (MICs <4 mg), were only moderately 
imipenem-resistant strains with MICs between 8 and 
32 mg/L, while highly imipenem-resistant strains 
(MIC 2 6 4  mg/L) were invariably meropenem resistant. 
The primary mechanism in carbapenem resistance 
of I? aeruginosa is directly related to the absence or 
diminished expression of porin OprD2, a selective 
permeation pathway for carbapenems, resulting in 
reduced uptake of antimicrobial agents [8]. The sus- 
ceptibility to meropenem of strains showing a low level 
of resistance to imipenem is possible because of another 
pathway for the translocation of meropenem across the 
outer membrane [22]. 
Masuda et al [23] described meropenem-resistant 
l? aeruginosa isolates which are susceptible to imipenem. 
This resistance was associated with overproduction 
of an outer-membrane protein presumably similar to 
OprM, an efflux pump implicated in intrinsic resistance 
[lo]. It was associated with cross-resistance to cephems 
and quinolones. Only 0.7% of strains resistant to mero- 
penem but susceptible to imipenem were found in our 
In conclusion, meropenem is a promising carba- 
penem with antimicrobial activity comparable or 
superior to that of imipenem against l? aeruginosa. It 
should be considered as an effective agent in therapy for 
l? aeruginora infections, with good activity against strains 
harboring resistance to p-lactam antibiotics. However, 
as with other antibiotics, we have to be careful of 
selection pressure encouraging the development of 
resistant strains. 
study. 
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During the last decade, Enterococcars has evolved as one 
of the most significant nosocomial pathogens, parti- 
cularly as an etiologic agent of nosocomial bloodstream 
infections [1,3]. The increase in incidence of entero- 
coccal infections is a consequence of their broad natural 
and acquired resistance to antimicrobial agents, several 
different reservoirs ofresistant strains, and, in particular, 
the acquisition of resistance to the glycopeptides, some- 
times leaving no therapeutic options in seriously ill 
patients [3]. 
The first clinical isolates of vancomycin-resistant 
enterococci (VRE) were dlscovered in 1986 by Leclercq 
et a l  in France [4] and by Uttley et a1 in the UK [5]. 
Both outbreaks involved both Enterococcus faecalis and 
E. faecium, and the strains demonstrated high-level 
resistance to vancomycin and teicoplanin. 
Four phenotypes of vancomycin resistance, VanA, 
VanB, VanC and VanD, have been reported. Genes 
determining the VanA and VanB phenotypes are usually 
located on transposons that are often plasmid-mediated, 
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Figure 1 RAPD products obtained in  PCR reactions using ERIC1, AP4 and ERICl/AP4 primers. Molecular size markers 
are indicated (Si, h/BstEII; S2, pBR 322/hhpI). Lane 1, isolate 1 (1639); lane 2, isolate 2 (1640); lane 3, isolate 3 (1641). 
